Current treatments and perceptions of genital herpes: A European-wide view

Journal of the European Academy of Dermatology and Venereology

Volumn 16, Issue 6, 2002, Pages 564-572

  Strand, A ^a   Barton, S ^b   Alomar, A ^c   Kohl, P ^d   Kroon, S ^e   Moyal Barracco, M ^f   Munday, P ^g   Paavonen, J ^h   Volpi, A ⁱ  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY OF BERGEN   (Norway)

^f Watford General Hospital ^*  (France)

^g WATFORD GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Delivery of health care; Dermatology; Epidemiology; Public health; Sexually transmitted diseases; Virology

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANALGESIC AGENT; ANTIVIRUS AGENT; CYTOKINE; FAMCICLOVIR; FOSCARNET; IMIQUIMOD; INTERLEUKIN 12; LIDOCAINE; NUCLEOSIDE ANALOG; PETROLATUM; RESIQUIMOD; SODIUM CHLORIDE; TRIFLURIDINE; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR; VIRUS ANTIBODY; VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURAL FACTOR; DISEASE TRANSMISSION; DOCTOR PATIENT RELATION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG MECHANISM; EUROPE; FEMALE; FINLAND; FRANCE; GENITAL HERPES; GERMANY; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE NEED; HUMAN; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NORWAY; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; SPAIN; SWEDEN; UNITED KINGDOM;

ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; AWARENESS; COUNSELING; DELIVERY OF HEALTH CARE; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HERPES GENITALIS; HUMANS; RECURRENCE;

EID: 0036853943     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2002.00663.x     Document Type: Article

References (50)

1. Lowhagen GB, Tunback P, Andersson Bergstrom T, Johannisson G. First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Inf 2000; 76: 179-182.
2. Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000; 181: 1454-1457.
3. International Herpes Management Forum. The medical importance of genital herpes simplex virus infection. In: Corey L, Simmons A, editors. Recommendations of the International Herpes Management Forum Management Strategies Workshop. Monograph, 1997. Available online at. http://www.ihmfcom.
4. Carney O, Ross E, Bunker C et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994; 70: 40-45.
5. Patel R, Boselli F, Cairo I et al. Patients' perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12: 640-645.
6. Brown ZA. HSV-2 specific serology should be offered routinely to antenatal patients. Rev Med Virol 2000; 10: 141-144.
7. Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000; 183: 400-406.
8. Sullivan AK, Straughair GJ, Marwood RP et al. A multidisciplinary vulva clinic: the role of genito-urinary medicine. J Eur Acad Dermatol Venereol 1999; 13: 36-40.
9. Patel R, Barton SE, Brown D et al. HSV Special Interest Group (of the Medical Society for the Study of Venereal Diseases, UK). European guidelines for the management of genital herpes. Int J STD AIDS 2001; 12 (Suppl. 3): 34-39.
10. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-1): 1-111.
11. Allason-Jones E. The Diploma in Genitourinary Medicine (London Society of Apothecaries). Sex Transm Infect 2001; 77: 81-83.
12. Benedetti J, Zeh J, Selke S, Corey L. Frequency and reactivation of nongenital recurrences among patients with genital herpes simplex virus. Am J Med 1995; 98: 237-242.
13. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National Guideline for the Management of Genital Herpes. 2001. Available online at. http://www.mssvd.org.uk/ceg.htm.
14. Linde A. The importance of specific virus diagnosis and monitoring for antiviral treatment. Antiviral Res 2001; 51: 81-94.
15. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337: 1105-1111.
16. Wheeler CE Jr. The herpes simplex problem. J Am Acad Dermatol 1988; 18 (1 Part 2): 163-168.
17. Wald A, Langenberg AG, Link K et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285: 3100-3106.
18. Stanberry LR, Cunningham A, Mertz G et al. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res 1999; 42: 1-14.
19. Patel R, Tyring S, Strand A et al. Impact of suppressive antiviral therapy on the health-related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75: 398-402.
20. Timonen P, Paavonen J. Suppressive therapy for recurrent genital herpes is underused. Int J STD AIDS 2001; 12 (Suppl. 2): 148-152.
21. Wald A. Herpes. Transmission and viral shedding. In: Freedman D, editor. Dermatol Clin 1998; 16(4): 795-797.
22. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124: 8-15.
23. Braig S, Luton D, Sibony O et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol 2001; 96: 55-58.
24. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45 (Topic T3): 1-8.
25. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000; 60: 1329-1352.
26. Spruance SL and the SmithKline Beecham Herpes Vaccine Efficacy Study Group, University of Utah School of Medicine, Salt Lake City, UT. Gender-specific efficacy of a prophylatic SBAS4-adjuvant gD subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials. Proceedings of the 40th Interscience Conference on Antimicrobrial Agents and Chemotherapy of the American Society for Microbiology, Toronto, Canada 2000 (Abstr.).
27. Stanberry LR, Cunningham AL, Mindel A et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000; 30: 549-566.
28. Bernstein DI. Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 2001; 8: 8-11.
29. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topically-applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001; 184: 196-200.
30. Malkin JE, Malvy D, Morand P et al. Seroprevalence of HSV-1 and HSV-2 infection in the French general population. 7th Annual Meeting of the International Herpes Management Forum, Seville, Spain 1999.
31. Janier M, Lassau F, Bloch J et al. Seroprevalence of herpes simplex virus type 2 antibodies in an STD clinic in Paris. Int J STD AIDS 1999; 10: 522-526.
32. Peltonen R. Antibodies to herpesvirus hominis types 1 and 2 among women with neoplastic change of uterine cervix. Acta Obstet Gynecol Scand 1975; 54: 36-372.
33. Arvaja M, Lehtinen M, Koskela P et al. Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Sex Transm Infect 1999; 75: 168-171.
34. Enders G, Risse B, Zauke M et al. Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay. Eur J Clin Microbiol Infect Dis 1998; 17: 870-872.
35. Wutzler P, Doerr HW, Farber I et al. Seroprevalence of herpes simplex virus type 1 and 2 in selected German populations-relevance of the incidence of genital herpes. J Med Virol 2000; 61: 201-207.
36. Suligoi B, Cusan M, Santopadre P et al. HSV-2 specific seroprevalence among various populations in Rome, Italy. Sex Transm Infect 2000; 76: 213-216.
37. Suligoi B, Dorrucci M, Volpi A et al. Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. AIDS 2001; 15: 133-135.
38. Cusini M, Cusan M, Parolin C et al. Seroprevalence of herpes simplex virus type 2 infection among attendees of a sexually transmitted disease clinic in Italy. Italian Herpes Forum. Sex Transm Dis 2000; 27: 292-295.
39. Eskild A, Jeansson S, Hagen JA, Skrondal A. Herpes simplex virus type-2 antibodies in pregnant women: the impact of the stage of pregnancy. Epidemiol Infect 2000; 125: 685-692.
40. Garcia-Corbeira P, Dal-Re R, Aguilar L et al. Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? J Med Virol 1999; 59: 194-197.
41. Gil A, Gonzalez A, Dal-Re R et al. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect 1998; 36: 53-56.
42. Varela JA, Garcia-Corbeira P, Aguanell V et al. Herpes simplex virus type 2 seroepidemiology in Spain. Prevalence and seroconversion rate among sexually transmitted disease clinic attendees. Sex Transm Dis 2001; 28: 47-50.
43. Forsgren M, Skoog E, Jeansson S, Olofsson S, Giesecke J. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969,1983 and 1989: implications for STD epidemiology. Int J STD AIDS 1994; 5: 113-116.
44. Cowan FM, Johnson AM, Ashley R et al. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. Br Med J 1994; 309: 1325-1329.
45. Woolley PD, Chandiok S, Pumphrey J et al. Serological prevalence of herpes simplex virus type 2 amongst GUM clinic attenders in a district general hospital setting. Int J STD AIDS 2000; 11: 379-382.
46. Vyse AJ, Gay NJ, Slomka MJ et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76: 183-187.
47. Petzoldt D, Gross G, editors. German STD guidelines for herpes genitalis. Diagnostik und Therapie Sexuell Übertragbarer Krankheiten-Leitlinien 2001 der Deutschen STD-Gesellschaft. Springer-Verlag, New York, 2001: 52-57.
48. Italian Guidelines of Dermatology [No Authors listed panel of experts.] Protocolli di diagnosi e terapia delle malattie sessualmente trasmesse di competenza dermatologica. G Ital Dermatol Venereol 1997; 132: 1-28.
49. Netherlands Association for Obstetrics and Gynaecology. Sexually Transmitted Diseases Diagnosis and Therapy Guidelines, 1997.
50. Norwegian Medicines Control Authority. Pharmacotherapeutics in Herpes Simplex, Varicella and Zoster. Norwegian Drug Bulletin, 1999; 22(2).